Therapeutic phages and methods thereof

DWPI Title: Producing engineered phage for killing bacterial colony by producing engineered phage genome that encodes engineered phage and comprising first prophage sequence (that is effective to kill target bacterium) that lacks integrase gene
Abstract: The present invention relates, in part, to engineered viruses (e.g., engineered phages), phage cocktails, and methods of producing and/or identifying viruses for targeting pathogenic bacteria.
Use: The method is useful for producing an engineered phage for killing a bacterial colony (claimed).
Novelty: Producing an engineered phage for killing a bacterial colony, involves identifying islands within a bacterial genome of a first bacterium; identifying a genomic island comprising a first prophage sequence within the bacterial genome from the first bacterium, identifying close relatives of the first prophage sequence by sorting the first prophage sequence into a group with other prophage sequences based on genomic distances computed amongst the first and other prophages; where the first prophage sequence comprises a genomic island comprising an integrase gene; identifying relatives of a target bacterium based on genomic distance measurements; producing an engineered phage genome comprising the first prophage sequence that lacks the integrase gene, where the first prophage sequence is effective to kill the target bacterium and the first bacterium is a relative of the target bacterium, where the engineered phage genome encodes the engineered phage; and targeting a bacterial colony.
Filed: 9/13/2019
Application Number: US16570197A
Tech ID: SD 14412.1
This invention was made with Government support under Contract No. DE-NA0003525 awarded by the United States Department of Energy/National Nuclear Security Administration. The Government has certain rights in the invention.
Data from Derwent World Patents Index, provided by Clarivate
All rights reserved. Republication or redistribution of Clarivate content, including by framing or similar means, is prohibited without the prior written consent of Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.